Poorly Differentiated Thyroid Gland Carcinoma: Clinical Trials

13 trials for Poorly Differentiated Thyroid Gland Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 active not recruiting, 4 completed, 1 terminated, 1 withdrawn. 13 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 213Active not recruiting 7, Completed 4, Terminated 1, Withdrawn 1

Follow Poorly Differentiated Thyroid Gland Carcinoma: new trials by email Literature Review of Poorly Differentiated Thyroid Gland Carcinoma trials Research Report on Poorly Differentiated Thyroid Gland Carcinoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
Lenvatinib, Pembrolizumab - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center252021-11-042026-08-10
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib - Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center302021-02-262026-11-10
Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
Lenvatinib, Pembrolizumab, Chemotherapy - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Phase 2WithdrawnSaint Petersburg State University, Russia2020-12-282024-03-25
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Trametinib, Dabrafenib, PDR001 - Thyroid Cancer, Thyroid Cancer, Follicular
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center192020-09-022026-09-17
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)112020-02-102026-11-13
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Lenvatinib, Sorafenib, Cabozantinib - Thyroid Cancer, Thyroid Cancer, Medullary
Phase 2TerminatedH. Lee Moffitt Cancer Center and Research Institute62018-08-062021-07-14
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma
Phase 2Active not recruitingM.D. Anderson Cancer Center302018-04-272026-11-10
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Laboratory Biomarker Analysis, Lenvatinib, Lenvatinib Mesylate - Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Phase 2CompletedAcademic and Community Cancer Research United572018-02-072025-08-29
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
Atezolizumab, Bevacizumab, Cobimetinib - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center502017-07-272026-07-24
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Iodine I-131, Placebo Administration, Selumetinib - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Phase 2CompletedAcademic and Community Cancer Research United602015-05-042024-07-26
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
Computed Tomography, Iodine I 124, Iodine I-131 - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)342014-08-142026-11-13
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Cabozantinib S-malate, Laboratory Biomarker Analysis - Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)252013-05-082018-04-03
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Laboratory Biomarker Analysis - Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)572004-10-252026-11-12

Narrower conditions

Thyroid Neoplasms (11)  ·  Thyroid Cancer, Papillary (9)  ·  Adenocarcinoma, Follicular (8)  ·  Thyroid Carcinoma, Anaplastic (5)  ·  Thyroid cancer, Hurthle cell (3)  ·  Carcinoma, Medullary (2)  ·  Adenoma, Oxyphilic (1)  ·  Bone Neoplasms (1)  ·  Giant Cell Tumor of Bone (1)  ·  Histiocytoma, Malignant Fibrous (1)  ·  Osteosarcoma (1)  ·  Ovarian Neoplasms (1)  ·  Sarcoma (1)  ·  Thyroid Diseases (1)  ·  Thyroid cancer, follicular (1)

Broader conditions

Endocrine Gland Neoplasms (13)  ·  Endocrine System Diseases (13)  ·  Neoplasms (13)  ·  Neoplasms by Site (13)  ·  Carcinoma (12)  ·  Head and Neck Neoplasms (12)  ·  Neoplasms by Histologic Type (12)  ·  Neoplasms, Glandular and Epithelial (12)  ·  Thyroid Diseases (11)  ·  Adenocarcinoma (9)  ·  Adenocarcinoma, Papillary (9)  ·  Carcinoma, Neuroendocrine (2)  ·  Neoplasms, Ductal, Lobular, and Medullary (2)  ·  Neoplasms, Germ Cell and Embryonal (2)  ·  Neoplasms, Nerve Tissue (2)

Interventions

lenvatinib (4)  ·  Magnetic Resonance Spectroscopy (3)  ·  pembrolizumab (3)  ·  CTLA-4 Antigen (2)  ·  Iodine-131 (2)  ·  Ipilimumab (2)  ·  Nivolumab (2)  ·  Sorafenib (2)  ·  cabozantinib (2)  ·  trametinib (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  AZD 6244 (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Bevacizumab (1)  ·  Cyclophosphamide (1)

Sponsors

M.D. Anderson Cancer Center (4)  ·  National Cancer Institute (NCI) (4)  ·  Academic and Community Cancer Research United (2)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Saint Petersburg State University, Russia (1)

Countries

United States (12)  ·  Russia (1)

Top investigators

Alan L Ho (2)  ·  Maria E Cabanillas (2)  ·  Alan L Ho, MD, PhD (1)  ·  Amir A Jazaeri (1)  ·  Bhavana Konda (1)  ·  Bryan R Haugen (1)  ·  Christine H. Chung, M.D. (1)  ·  Manisha H Shah (1)  ·  Manisha Shah (1)  ·  Mark Zafereo (1)  ·  Yuliya Mikheeva, M.D., Ph.D. (1)

Results publications

PMID 33720068, PMID 28817373, PMID 39133806, PMID 39446377, PMID 42673705

NIH funding

P30CA015083 (2), P30CA016058 (2), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM62206 (1), N01CM62207 (1), P30CA008748 (1), P50CA172012 (1), R01CA184724 (1), U01CA076576 (1), UM1CA186705 (1), UM1CA186712 (1)